{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:54:00Z","timestamp":1762034040860,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014235","name":"US WorldMeds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In adults with chronic pain, mild-to-moderate withdrawal symptoms during medically directed opioid tapering in the outpatient setting may not be accompanied by hypertension or tachycardia. This clinical scenario could limit the use of lofexidine at dosages reported in clinical trials of opioid withdrawal precipitated by abrupt opioid discontinuation. Thus, the primary aim of this prospective case series is to describe the use of low dose lofexidine for opioid withdrawal in patients with chronic pain undergoing medically directed opioid tapering in an outpatient setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Six patients (white 5, Latino 1) admitted to an outpatient interdisciplinary pain rehabilitation program met inclusion and exclusion criteria. Patients self-selected to undergo medically directed opioid tapering, and the medication the patients were prescribed upon admission was used in the taper schedule. Upon initiation of the opioid taper, patients received 0.18\u00a0mg of lofexidine every 6\u00a0hours. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five of the six patients were women, and the median morphine milligram equivalents at baseline were 36.9. The median taper duration was 15\u00a0days, and the median duration of lofexidine administration was 14\u00a0days. Withdrawal scores were mild throughout the taper in four patients, and two patients with fibromyalgia experienced single episodes of moderately severe withdrawal symptoms at the median morphine milligram equivalent midpoint of the taper. No hypotension or sustained bradycardia were observed, and no adverse effects related to lofexidine were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The observations from this prospective case series suggest that low-dose lofexidine may be a feasible adjunct medication to attenuate withdrawal symptoms in adults with chronic pain undergoing outpatient opioid tapering.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04309-x","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T01:42:51Z","timestamp":1705455771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low dose lofexidine for medically directed outpatient opioid tapering in adults with chronic pain: a prospective case series"],"prefix":"10.1186","volume":"18","author":[{"given":"Megan M.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan D.","family":"Eberhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafisseh S.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-6355","authenticated-orcid":false,"given":"W. Michael","family":"Hooten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"4309_CR1","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1177\/1060028019828954","volume":"53","author":"B Doughty","year":"2019","unstructured":"Doughty B, Morgenson D, Brooks T. Lofexidine: A Newly FDA-approved, nonopioid treatment for opioid withdrawal. Ann Pharmacother. 2019;53:746\u201353.","journal-title":"Ann Pharmacother"},{"key":"4309_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1345\/aph.1M347","volume":"44","author":"EC Gish","year":"2010","unstructured":"Gish EC, Miller JL, Honey BL, Johnson PN. Lofexidine, an alpha2-receptor agonist for opioid detoxification. Ann Pharmacother. 2010;44:343\u201351.","journal-title":"Ann Pharmacother"},{"key":"4309_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","volume":"62","author":"JA Giovannitti Jr","year":"2015","unstructured":"Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62:31\u20139.","journal-title":"Anesth Prog"},{"key":"4309_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/(SICI)1096-9861(19980504)394:2<218::AID-CNE6>3.0.CO;2-5","volume":"394","author":"A Lee","year":"1998","unstructured":"Lee A, Rosin DL, Van Bockstaele EJ. Ultrastructural evidence for prominent postsynaptic localization of alpha2C-adrenergic receptors in catecholaminergic dendrites in the rat nucleus locus coeruleus. J Comp Neurol. 1998;394:218\u201329.","journal-title":"J Comp Neurol"},{"key":"4309_CR5","doi-asserted-by":"publisher","first-page":"R287","DOI":"10.1152\/ajpregu.00123.2002","volume":"283","author":"M Philipp","year":"2002","unstructured":"Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002;283:R287-295.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"4309_CR6","first-page":"760","volume":"219","author":"JC van Meel","year":"1981","unstructured":"van Meel JC, de Jonge A, Timmermans PB, van Zwieten PA. Selectivity of some alpha adrenoceptor agonists for peripheral alpha-1 and alpha-2 adrenoceptors in the normotensive rat. J Pharmacol Exp Ther. 1981;219:760\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"4309_CR7","first-page":"CD002024","volume":"2016","author":"L Gowing","year":"2016","unstructured":"Gowing L, Farrell M, Ali R, White JM. Alpha(2)-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;2016:CD002024.","journal-title":"Cochrane Database Syst Rev"},{"key":"4309_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0376-8716(98)00040-4","volume":"50","author":"T Carnwath","year":"1998","unstructured":"Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998;50:251\u20134.","journal-title":"Drug Alcohol Depend"},{"key":"4309_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0376-8716(96)01316-6","volume":"44","author":"A Kahn","year":"1997","unstructured":"Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 1997;44:57\u201361.","journal-title":"Drug Alcohol Depend"},{"key":"4309_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0376-8716(97)00116-6","volume":"48","author":"SK Lin","year":"1997","unstructured":"Lin SK, Strang J, Su LW, Tsai CJ, Hu WH. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997;48:127\u201333.","journal-title":"Drug Alcohol Depend"},{"key":"4309_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/jclp.20322","volume":"62","author":"CO Townsend","year":"2006","unstructured":"Townsend CO, Bruce BK, Hooten WM, Rome JD. The role of mental health professionals in multidisciplinary pain rehabilitation programs. J Clin Psychol. 2006;62:1433\u201343.","journal-title":"J Clin Psychol"},{"key":"4309_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/PHM.0b013e31817c124f","volume":"87","author":"RA Crisostomo","year":"2008","unstructured":"Crisostomo RA, Schmidt JE, Hooten WM, Kerkvliet JL, Townsend CO, Bruce BK. Withdrawal of analgesic medication for chronic low-back pain patients: improvement in outcomes of multidisciplinary rehabilitation regardless of surgical history. Am J Phys Med Rehabil. 2008;87:527\u201336.","journal-title":"Am J Phys Med Rehabil"},{"key":"4309_CR13","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/j.1526-4637.2010.00962.x","volume":"11","author":"WM Hooten","year":"2010","unstructured":"Hooten WM, Mantilla CB, Sandroni P, Townsend CO. Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering. Pain Med. 2010;11:1587\u201398.","journal-title":"Pain Med"},{"key":"4309_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/ADM.0000000000000474","volume":"13","author":"M Fishman","year":"2019","unstructured":"Fishman M, Tirado C, Alam D, Gullo K, Clinch T, Gorodetzky CW. Safety and efficacy of lofexidine for medically managed opioid withdrawal: a randomized controlled clinical trial. J Addict Med. 2019;13:169\u201376.","journal-title":"J Addict Med"},{"key":"4309_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drugalcdep.2017.02.020","volume":"176","author":"CW Gorodetzky","year":"2017","unstructured":"Gorodetzky CW, Walsh SL, Martin PR, Saxon AJ, Gullo KL, Biswas K. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug Alcohol Depend. 2017;176:79\u201388.","journal-title":"Drug Alcohol Depend"},{"key":"4309_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/jps.21401","volume":"98","author":"AM Al-Ghananeem","year":"2009","unstructured":"Al-Ghananeem AM. Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. J Pharm Sci. 2009;98:319\u201326.","journal-title":"J Pharm Sci"},{"key":"4309_CR17","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(20)30852-7","volume":"395","author":"AB Srivastava","year":"2020","unstructured":"Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020;395:1938\u201348.","journal-title":"Lancet"},{"key":"4309_CR18","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.pain.2011.07.005","volume":"152","author":"MA Ferreira-Valente","year":"2011","unstructured":"Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011;152:2399\u2013404.","journal-title":"Pain"},{"key":"4309_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1037\/1040-3590.7.4.524","volume":"7","author":"MJL Sullivan","year":"1995","unstructured":"Sullivan MJL, Scott RB, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7:524.","journal-title":"Psychol Assess"},{"key":"4309_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1023\/B:JOBM.0000042410.34535.64","volume":"27","author":"JL D'Eon","year":"2004","unstructured":"D\u2019Eon JL, Harris CA, Ellis JA. Testing factorial validity and gender invariance of the pain catastrophizing scale. J Behav Med. 2004;27:361\u201372.","journal-title":"J Behav Med"},{"key":"4309_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1023\/A:1025570508954","volume":"20","author":"A Osman","year":"1997","unstructured":"Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O\u2019Neill E. Factor structure, reliability, and validity of the Pain Catastrophizing Scale. J Behav Med. 1997;20:589\u2013605.","journal-title":"J Behav Med"},{"key":"4309_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253\u20139.","journal-title":"J Psychoactive Drugs"},{"key":"4309_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.drugalcdep.2009.07.001","volume":"105","author":"DA Tompkins","year":"2009","unstructured":"Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105:154\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"4309_CR24","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/add.15743","volume":"117","author":"JP Connor","year":"2022","unstructured":"Connor JP, Stjepanovic D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction. 2022;117:2075\u201395.","journal-title":"Addiction"},{"key":"4309_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2474-5-48","volume":"5","author":"JN Baraniuk","year":"2004","unstructured":"Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord. 2004;5:48.","journal-title":"BMC Musculoskelet Disord"},{"key":"4309_CR26","doi-asserted-by":"publisher","first-page":"10000","DOI":"10.1523\/JNEUROSCI.2849-07.2007","volume":"27","author":"RE Harris","year":"2007","unstructured":"Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27:10000\u20136.","journal-title":"J Neurosci"},{"key":"4309_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4637.2007.00253.x","volume":"8","author":"WM Hooten","year":"2007","unstructured":"Hooten WM, Townsend CO, Sletten CD, Bruce BK, Rome JD. Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. Pain Med. 2007;8:8\u201316.","journal-title":"Pain Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04309-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04309-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04309-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T01:43:27Z","timestamp":1705455807000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04309-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4309"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04309-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the Mayo Foundation Institutional Review Board and patients provided signed informed consent prior to study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}